

Draft Guidance for Industry and FDA Staff

Pharmacogenetic Tests and Genetic Tests for Heritable Markers

Document issued on: February 9, 2006

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Alternatively, electronic comments may be submitted to <http://www.fda.gov/dockets/ecomments>. All comments should be identified with the docket number 2006D-0012.

For questions regarding this document contact Robert Becker at 240-276-0493 x 212, email robert.becker1@fda.hhs.gov, or Maria Chan at 240-276-1293 x130, email maria.chan@fda.hhs.gov.

For questions regarding proposed use of this document in relation to applications to CBER or, contact CBER's Office of Communications, Training, and Manufacturers Assistance at 800-835-4709 or 301-827-1800. For questions relating to applications to CDER, contact Allen Rudman at 301-827-7691, or Office of Clinical Pharmacology and Biopharmaceutics, HFD-850 5600 Fishers Lane, Rockville MD 20857

This draft document replaces the draft guidance document "Multiplex Tests for Heritable DNA Markers, Mutations and Expression Patterns; Draft Guidance for Industry and FDA Reviewers," dated February 27, 2003.



**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research**

Preface

Comments

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Alternatively, electronic comments may be submitted to <http://www.fda.gov/dockets/ecomments>. All comments should be identified with the docket number 2006D-0012.

Additional Copies

Additional copies are available from the Internet at: <http://www.fda.gov/cdrh/oivd/guidance/1549.pdf>, or to receive this document by fax, call the CDRH Facts-On-Demand system at 800-899-0381 or 301-827-0111 from a touch-tone telephone. Press 1 to enter the system. At the second voice prompt, press 1 to order a document. Enter the document number 1549 followed by the pound sign (#). Follow the remaining voice prompts to complete your request.

Table of Contents

| | |
|--|----|
| Introduction | 1 |
| I. Purpose..... | 1 |
| II. Pharmacogenetic Testing versus Genetic Testing | 3 |
| III. Recommendations for the Preparation of the Pharmacogenetic or Genetic Test Applications | 3 |
| A. Intended Use of a Device..... | 3 |
| B. Device Design..... | 4 |
| C. Analytical Studies | 6 |
| D. Software and Instrumentation | 9 |
| E. Comparison studies using clinical specimens..... | 10 |
| F. Clinical Evaluation Studies Comparing Device Performance to Accepted Diagnostic Procedure(s) | 12 |
| G. Clinical Effectiveness of the Device..... | 13 |
| IV. Labeling | 14 |
| Appendix I: General considerations for planning and evaluating clinical studies | 16 |

Draft Guidance for Industry and FDA Staff

Pharmacogenetic Tests and Genetic Tests for Heritable Markers

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

Introduction

I. Purpose

This draft guidance document is intended to facilitate progress in the field of pharmacogenomics and genetics by helping to shorten development and review timelines, facilitate rapid transfer of new technology from the research bench to the clinical diagnostic laboratory, and encourage informed use of pharmacogenomic and genetic diagnostic devices. It provides recommendations to sponsors and FDA reviewers in preparing and reviewing premarket approval applications (PMA) and premarket notification (510(k))¹ submissions for pharmacogenetic and other human genetic tests, whether testing is for single markers or for multiple markers simultaneously (multiplex tests). Array-based tests (commonly referred to as microarrays) are a subset of multiplex tests and are included in the scope of this draft document. The recommendations within this draft guidance for elements of a genetic test submission apply to pharmacogenetic [e.g., drug-metabolizing enzyme allele tests, single nucleotide polymorphism (SNP) analysis] and other types of genetic tests. Tests of gene expression and tests for non-heritable (somatic) mutations are not specifically addressed, although many of the same principles may apply. In addition, this draft guidance considers nucleic acid-based analysis only, but the principles may be applied to other matrices (e.g., protein) when the purpose is to provide genetic information.

¹ For discussion of PMA and 510(k) submissions, see topics on the following website:
<http://www.fda.gov/cdrh/devadvice>

Draft – Not for Implementation
Contains Nonbinding Recommendations

This draft document is intended to recommend a basic framework for the types of data and regulatory issues that we believe should be addressed in a genetic test submission and provide a common baseline from which both manufacturers and scientific reviewers can operate. The recommendations contained in this draft document are purposefully general. It is well-known that each testing system will have an associated unique set of concerns, and we expect to identify and discuss these unique concerns with individual manufacturers, for example, through pre-IDE submission meetings.

Although this draft document focuses on information to include in a 510(k), the general types of information are likely to be the same for PMAs. However, we may request different types of data and statistical analyses in PMAs. The appropriate information depends on the following:

- intended use (for example, to detect cytochrome P450 enzyme alleles)
- indications for use (for example, predictive or prognostic for disease, treatment response, or drug sensitivity)
- methodology (for example, polymerase chain reaction)
- technical interpretation of results (for example, positive for variant alleles)
- quality control and assay limitations
- performance (see sections C-E below)
- clinical validity (for example, false positives and negatives, see sections F-G below)
- clinical interpretation
- benefits and risks
- claims made by the manufacturer (for example, effectiveness)

Technical aspects of this guidance may also be useful for other FDA applications that utilize these assay formats in support of product development, e.g., Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and New Drug Applications (NDAs). We recommend that the sponsor or manufacturer consult with the appropriate review Office within the Center for Biologics Evaluation and Research (CBER) or Center for Drug Evaluation (CDER) for these types of applications.

The appropriate type of submission depends on claims and information available regarding the specific device. We expect most pharmacogenetic and genetic device submissions will primarily be traditional 510(k)s or de novo classifications. However, some devices will require submission of a PMA (see sections 513 and 515 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360c, 360e)). We recommend that the sponsor or manufacturer consult with the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), to determine the appropriate type of submission. We also suggest that sponsors consider submitting protocols (“pre-IDEs”) before carrying out studies to ensure review issues are addressed and resolved prior to submission of a 510(k) or PMA. Additional information on submission of pharmacogenomic information can be found in the “Guidance for Industry: Pharmacogenomic Data Submissions” (<http://www.fda.gov/cder/guidance/6400fnl.pdf>).

Draft – Not for Implementation
Contains Nonbinding Recommendations

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

The Least Burdensome Approach

This draft guidance document reflects our careful review of what we believe are the relevant issues related to pharmacogenetic tests and genetic tests for heritable markers and what we believe would be the least burdensome way of addressing these issues. If you have comments on whether there is a less burdensome approach, however, please submit your comments as indicated on the cover of this document.

II. Pharmacogenetic Testing versus Genetic Testing

Fundamentally, testing for pharmacogenetic polymorphisms and genetic mutations is the same, and yields the same general types of results. The target populations and how the results of the test are used, however, are expected to be quite different. We consider pharmacogenetic tests for clinical use to be mostly those that are intended to provide information that may aid in selection of certain therapeutics. When sufficient clinical information is available they may also aid in dosage selection of the therapeutic. Therefore, a pharmacogenetic test target population will typically be composed of candidates for a particular therapeutic. Target populations of genetic tests, on the other hand, will usually be composed of those who are suspected of having, or are at risk of developing, a particular disease or condition. The following recommendations will apply to both types of tests unless noted otherwise.

III. Recommendations for the Preparation of the Pharmacogenetic or Genetic Test Applications

The following are areas that you should address in the preparation of a submission for a medical device that measures pharmacogenetic or genetic information.

A. Intended Use of a Device

An application for premarket approval or clearance of a device must include a statement of the intended use of the device. 21 CFR 807.92(a)(5), 814.20(b)(3)(i). The intended use of the device for which approval or clearance is sought should specify the marker the device is intended to measure, the clinical purpose of measuring the marker, and the populations to which the device is targeted, where appropriate.

Draft – Not for Implementation
Contains Nonbinding Recommendations

Some devices may have multiple intended uses. We encourage separate applications for each intended use, if each has unique and separate supporting studies; however, in certain cases of pharmacogenetic tests, we would consider application of test results in multiple therapeutic settings as a single intended use. For example, determination of CYP2D6 alleles for the purpose of providing information to aid in drug selection, without reference to a particular drug, would be an appropriate single intended use, given that it is well known that CYP2D6 affects the metabolism of many drugs. In other cases, it may be necessary to identify multiple intended uses. For example, a genetic test for a disease-causing mutation could be used for testing for carriers, prenatal testing, or for diagnosis. Each of these scenarios would have studies using different populations. In addition, the different uses might have different risk profiles, and therefore might have separate intended use claims and submissions. In these cases, you should provide appropriate data to support each claimed intended use. You should consult the appropriate review divisions in OIVD, for advice on submitting tests with multiple intended uses.

In this document, "screening" as an intended use is considered to be an indication to test patients regardless of symptomology, background, or clinical need for test information before therapeutic intervention. We recommend that if you are presenting data to support this type of intended use, you carefully consider the issues listed below. The following issues also apply to any test that evaluates rare events, such as mutations or variants, within the indicated population(s).

- Some alleles, genotypes, and mutations will have very low prevalence in given populations. In these cases, samples from many patients should be obtained in order to detect a significant number of positives. Furthermore, some alleles, genotypes, or mutations might only be present in particular ethnic groups, which should therefore participate in the study in significant numbers. Enrichment can be undesirable because sensitivity can be affected by spectrum bias due to irregular retrospective selection of cases and because predictive values are dependent on the prevalence in the intended use population, which cannot be characterized from such a study.
- When many samples are tested for rare events, false positive results could become problematic in that they may be more common than true positives, due to test error and low prevalence.
- For predictive screening in healthy or asymptomatic individuals, long-term follow-up (i.e., a longitudinal study) may be the only way to prove that the test was indeed predictive and to evaluate issues such as penetrance.

We recommend that you consult OIVD about study design if your device is intended for screening or detection of rare mutations or variants.

B. Device Design

Draft – Not for Implementation
Contains Nonbinding Recommendations

An application for premarket approval or clearance of a device must include information on the design of the device. 21 CFR 807.92(a)(4), 814.20(b)(3)(ii), 814.20(b)(4). We recommend that you carefully characterize design of pharmacogenetic and genetic testing devices. For example, you should describe the following elements where applicable:

- overall design of the test, including quality control of feature identity and placement, where applicable
- platform (e.g., flow cytometry, arrayed elements)
- assay components such as buffers, enzymes, fluorescent dyes, chemiluminescent reagents, other signaling and signal amplification reagents, instruments, software, etc.
- internal controls and external controls that you recommend or provide
- sequence or identity of oligonucleotides, primers, probes, or other capture elements
- hybridization conditions, washing procedures, and drying conditions (e.g., temperature, length of time)
- composition and spatial layout of arrays or other spatially fixed platforms
- methods used in attaching the probe material to a solid surface, if applicable
- specificity of probes for locus of interest; this is especially important when pseudogenes or sequence-related genes exist
- range of input sample concentrations that meet performance specifications
- stability and reproducibility of the platform when used for its intended use
- for multiplex tests in which the target molecules will contact a number of different probes, the design and functional testing to address the potential for specific and non-specific probe cross-hybridization
- for multiplex tests in which many probes are handled during the manufacturing process, the design and functional testing to address potential for probe cross-contamination during manufacturing

We recommend that you describe in detail the test system's methodology for detecting alleles, genotypes, or mutations. You should briefly outline your risk analysis relating to the test system methodology and describe device design elements that resulted from optimization of the test system for the analyte to be tested, if applicable.

If you plan to provide reagents for sample preparation with your test, you should describe the methodology and the risk analysis associated with specimen preparation and other applicable preanalytical elements.

We recommend that you include illustrations or photographs of non-standard equipment or methods because these can be helpful in understanding novel methodologies and your approach to risk management, including incorporation of features to minimize potential device failures and user errors.

C. Analytical Studies

For performance data that is included in your 510(k) (21 CFR 807.92(b)), or PMA (21CFR814.20(b)(3)(v)), we recommend that you describe the analytical studies you used to evaluate the following performance characteristics, including protocols and results. Where applicable, you should include the following information for each allele, genotype, or mutation and for each matrix claimed in the intended use statement:

1. General analytical performance considerations

You should demonstrate the device's ability to accurately and reproducibly differentiate genotypes, alleles, or mutations using nucleic acid levels that span the input concentrations recommended in product labeling. When fresh samples for rare alleles, genotypes, or mutations are scarce, we will consider the use of archived or retrospective samples. Although natural samples are preferred, we will also consider artificially prepared materials, such as plasmid DNA or amplified gene segments. These artificially prepared materials should mimic natural matrices to the greatest degree possible. In particular, when using cloned or amplified material, the copy number tested should approximate that found in a natural sample. You should demonstrate that your assay can distinguish between hetero- and homozygotes, since this is one of the critical aspects in assessing analytical performance of a genetic assay.

2. Sample characterization and specifications

If you intend to provide reagents for specimen processing, you should demonstrate that the chosen sample preparation method consistently provides quality nucleic acid samples that yield reproducible test results for each specimen type with which your test is intended to be used. (See also Section 4, Precision.) If your sample preparation method involves preparation of an RNA intermediate, you should evaluate your procedure to ensure that there is no residual contaminating genomic DNA. If you do not intend to provide sample preparation reagents in your kits, you should provide specifications for assessing the quality of the assay input sample so that users can validate their own sample preparation method and reagents. You should provide justification for these specifications in the submission. We also recommend that you carefully characterize sample stability and validate your storage and handling recommendations.

3. Effect of excess sample and limited sample

You should investigate the range of nucleic acid sample concentrations that reproducibly yield acceptable results. You should also determine the

***Draft – Not for Implementation
Contains Nonbinding Recommendations***

minimum amount of testable input DNA sample that provides acceptable performance and approximate the amount of patient specimen needed to generate this minimum amount of sample. We recommend that you determine the minimum amount of input nucleic acid needed to obtain a correct genotype, such that the lower bound of the 95% confidence interval for the estimated “correct call” fraction is greater than 95%. The recommended minimum sample input in your labeling may fall above this amount in order to improve performance of the test.

4. Precision (Repeatability/Reproducibility)

You should perform studies to determine estimates of total variability for each specimen type. For information on precision studies, we recommend that you consult “Evaluation of Precision Performance of Clinical Chemistry Devices;” Approved Guideline-2nd Edition, CLSI (Clinical Laboratory Standards Institute), EP5-A2 and “User Protocol for Evaluation of Qualitative Test Performance;” Approved Guideline, CLSI, EP12-A. Information on obtaining these documents is available at <http://www.clsi.org/>. You should include, as appropriate, repeatability (same day, site, operator, instrument, and lot) and reproducibility (between runs, days, sites, operators, instruments, and lots) studies. Precision panel test samples should contain nucleic acid levels that span the input concentrations recommended in product labeling. You should carry out reproducibility at three or more sites. Multiple operators with skill levels the same as those of your intended users, should perform the test, preferably using multiple lots of devices and reagents. You should also perform testing over several weeks and at different times of the day to maximize detection of potential sources of variability. The protocol should include evaluation of sample preparation reagents provided with the kit. If you do not include sample preparation reagents in the test kit, each site should use and validate its own specimen processing procedures and demonstrate that the resulting sample meets manufacturer-supplied specifications. Likewise, if you do not include or recommend a specific instrument with the kit, each site should use its own instrument during testing, as appropriate.

5. Controls and calibrators

For external controls and calibrators, you should describe the following:

- nucleic acid levels
- matrix
- your method of preparation, value assignment, and validation
- your protocol and acceptance criteria for determining stability
- how you established the recommended calibration and control testing frequency

If you do not provide external controls or calibrators, you should indicate commercial availability of these materials or describe a method that users can

Draft – Not for Implementation
Contains Nonbinding Recommendations

follow to prepare them (or both). You should describe the reactions and functions monitored by internal controls. For different technologies, these controls may differ, but the controls should enable users to determine if critical reactions have proceeded properly. Controls should contain nucleic acid levels that span the input concentrations recommended in product labeling in order to adequately stress the system.

6. Cut-off

We recommend you provide the following to support an analytical characterization of your cut-off(s), if applicable:

- study design and analytical data to support the established cut-off
- rationale for the units, cut-off, and/or categories of the results
- a description of specimen preparation, including analyte levels, matrix, and how levels were established
- statistical methods used [e.g., Receiver Operating Characteristic (ROC) Analysis]

7. Analytical specificity (interference and cross-reactivity studies)

Potential inhibitors present in patient specimens may not be efficiently removed by sample preparation procedures and may even interfere with sample preparation itself. We recommend that you examine potential interfering substances commonly present in the indicated patient specimens for their effects on sample preparation and assay performance. Test samples should contain nucleic acid levels that span the input concentrations recommended in product labeling. For more information on interference studies we recommend that you consult “Interference Testing in Clinical Chemistry,” Approved Guideline, CLSI, EP-7A. For both cross-reactive and interfering substances tested, we recommend you include the following:

- the concentrations at which these substances were present in the samples
- sample description and preparation including matrix and nucleic acid levels
- the number of replicates tested for each substance
- how interference and cross-reactivity were defined in relation to the results obtained for the reference positive and negative control samples
- a description of the degree of interference or cross-reactivity observed
- results demonstrating that your test rejects sequences similar to the target sequence, at nucleic acid levels that span the input concentrations recommended in product labeling

8. Assay conditions

Draft – Not for Implementation
Contains Nonbinding Recommendations

As applicable, you should verify hybridization conditions (for thermocycling, cycling conditions), concentration of reactants, and control of non-specific activity. In the case of multiplex tests, you should examine and describe optimization of multiple simultaneous target detection. When thermocycling is used, you should verify optimization, specificity, and robustness of amplification.

9. Potential for sample carryover and cross-hybridization

We recommend that you assess the potential for sample carryover and cross-hybridization, and that you provide instructions in your labeling for preventing carryover and reducing or eliminating cross-hybridization.

10. Limiting factors of the device

You should describe any known limitations of the device. Examples are when the device does not measure all possible alleles, genotypes, or mutations, or when the range of alleles, genotypes or mutations is not known.

D. Software and Instrumentation

1. Data processing

If your device includes software, you should include specific information about the software in your submission. We recommend that computational methods be developed and verified using the CDRH software development and validation guidance documents that are available at <http://www.fda.gov/search/databases.html>.

You should provide support for your selection of the appropriate level of concern. You also must demonstrate that the software design has been verified as required by 21 CFR 820.30(f). For more information on “levels of concern,” you should refer to FDA’s Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, May 11, 2005. (<http://www.fda.gov/cdrh/ode/guidance/337.pdf>). If applicable, you should describe how computational concerns such as probe saturation level, background correction, normalization, etc., are addressed by the software.

2. Validation of instrumentation

You should provide specifications in your labeling for any generic instrument needed to run the test, so that users may select an instrument that is suitable for their purposes. You should base your recommendations on performance testing of various instruments with your device (see Precision, Section C4,

Draft – Not for Implementation
Contains Nonbinding Recommendations

above). If you provide, or recommend, specific instrumentation for your device, whether manufactured by you or by another company, you should include specific information about the instrument(s) in your submission, and you should perform testing described in this guidance document using this instrument. We recommend that you describe the following and include test results to support your descriptions, where appropriate:

- a. Characterization: You should characterize the instruments. We recommend that you include information on how the instrument assigns values to or interprets assay variables such as feature location, size, concentration, volume, drying of small samples, effect of small volume reactions and its impact on test results.
- b. Calibration: You should describe how the instrument is calibrated and the materials used in calibration. You should indicate the recommended calibration frequency and how it was established.
- c. Uncertainties: You should describe potential sources and estimates of uncertainties in results introduced by hardware components such as scanners, LCD cameras, etc.

If you specify a particular instrument (by manufacturer or brand), you should assure that any changes made to the instrument (by you or the manufacturer) are tracked and evaluated to determine whether there is any effect on assay performance, in accordance with the quality system regulation (21 CFR Part 820). If changes in instrumentation introduce new or different assay performance issues, you will be responsible for validation of your device under the changed conditions and you should determine whether you need to submit this information to FDA. 21 CFR 820.30(g). (See <http://www.fda.gov/cdrh/ode/510kmod.html> and 21 CFR 807.81, 814.39.)

E. Comparison studies using clinical specimens

Where comparison studies are appropriate to establish performance of a device, we recommend that you describe your evaluation protocol and results, including the items listed below. You should include in your evaluation all matrix types with which your device is intended to be used.

1. Comparison to a Reference Method

For pharmacogenetic and genetic tests, we recommend that you validate your assay by performing studies which compare results obtained with your device to those obtained with bidirectional sequencing. Bidirectional sequencing is

Draft – Not for Implementation
Contains Nonbinding Recommendations

considered the reference method² for sequence analysis (sometimes also referred to as the “gold standard”). In your description of this study, you should include your protocol, the sample types you used, any selection criteria you applied, and results. If the population tested is representative of the population for which the device is intended, results are usually reported as clinical sensitivity and specificity. You should address the quality of the bidirectional sequencing by an appropriate metric and include it in your submission.

2. Comparison to another device

You may also choose to describe comparison studies with another well-characterized or predicate device, in addition to comparison with the reference method. You should generally report results as positive and negative percent agreement. While comparison to another device can be useful, FDA believes that the best measure of test performance will come from comparison to bidirectional sequencing.

3. Resolution of Comparison Discrepancies

You should identify discrepant results. If you perform discrepancy resolution, you should report the result of that testing. FDA strongly discourages the use of resolved results in calculations of device performance unless unbiased statistical techniques can be used. FDA is developing guidance on statistical analysis. When this guidance is finalized, you may reference it for further discussion of this subject. See the draft guidance, “Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests; Draft Guidance for Industry and FDA Reviewers” (<http://www.fda.gov/cdrh/osb/guidance/1428.pdf>).

4. Failure Rates

You should identify incorrect results obtained due to device failure. You should also provide estimates of expected failure rates (e.g., when result is “no call” due to device failure, sample inadequacy).

5. Evaluation of devices employing quantitative measurement techniques

You should evaluate the effects of random and systematic error in comparison to the reference method. You should calculate bias when possible and appropriate. For more information, you should also refer to “Method Comparison and Bias Estimation Using Patient Samples” Approved Guideline, 2nd Edition, CLSI, EP-9A2.

² In this document, we use the term “reference method” to refer to a well-validated analytical procedure sufficiently free of systematic or random error to make it useful for validating proposed new analytical procedures for the same analyte.

6. Confidence Intervals

For any device, you should calculate and report confidence intervals around the point estimates of performance measures.

F. Clinical Evaluation Studies Comparing Device Performance to Accepted Diagnostic Procedure(s)

Where clinical studies are needed to establish safety and effectiveness of a pharmacogenetic or genetic testing device, you should address the points listed below. You should include in your evaluation all matrix types with which your device is intended to be used. In addition, you may refer to Appendix I for more points to consider in designing studies. You should provide appropriate clinical data to support each intended use.

- a) You should define “clinical truth” as it will be used in evaluating the clinical performance of the device. For the purposes of this draft guidance, we define clinical truth as the best clinical evidence for a specific diagnosis or allele assignment. If you use discrepant resolution in your analysis, you should describe the strategy used.
- b) We recommend that you validate genotype/phenotype correlations, if necessary, on a statistically determined number of specimens for each intended use. You should include the following information, when defining the population(s) used:
 - Number of specimens from the normal population, summarized according to appropriate demographic characteristics.
 - Number of specimens included in each disease, condition, genotype, or group summarized according to appropriate demographic characteristics.
- c) You should include clinical samples for all matrices included in your intended use statement. For more information on evaluating matrix effects see “Evaluation of Matrix Effects” Approved Guideline, CLSI, EP-14A.
- d) Clinical cut-off (where applicable): You should describe clinical validation of the established cut-off and its validation for the new device. You should identify clinical cut-off points in a training set and validate these in a separate test data set. You may also provide literature references that support clinical cut-offs.
- e) You should describe statistical methods used and confidence intervals for calculations, where appropriate.

Draft – Not for Implementation
Contains Nonbinding Recommendations

- f) For some pharmacogenetic polymorphisms and genetic mutations (e.g. CYP2D6 alleles), there may be a sufficient literature base to establish clinical validity with the new test without extensive clinical studies. When you propose literature to support clinical validity, you should include a summary of balanced and representative published information and clinical data pertinent to the device. In some cases, unpublished data may also be acceptable as supporting material. When literature is intended to support bridging from analytical to clinical performance, the literature should identify the same technology as the new test and a similar patient population. We recommend that you consult OIVD to determine the suitability of literature, and techniques for its evaluation, to supplement or substitute for clinical performance studies. In some cases, a direct reference to a professional statement or guideline may be an appropriate inclusion in the intended use statement. You should consult with FDA to determine the suitability of reference to such statements or guidelines.

G. Clinical Effectiveness of the Device

For PMAs, you must provide valid scientific evidence to establish reasonable assurance of the safety and effectiveness of the new device and for de novo classification submissions, you must provide valid scientific evidence to establish which general and special controls are necessary to provide a reasonable assurance of safety and effectiveness of the device (see sections 513 and 515 of the Act (21 U.S.C. 360c, 360e)). For both types of submissions, we recommend you submit clinical data.

1. New markers

Clinical performance validation of your new markers, mutations, patterns, and other outputs of pharmacogenetic and genetic tests must meet the rules for determining safety and effectiveness for the tests' intended use, as outlined in 21 CFR 860.7.

2. Established Markers

When you validate test performance using clinical specimens, you may use appropriate information in the medical literature as evidence of the effectiveness of the marker or mutation. If you use peer-reviewed literature to support effectiveness, you should provide copies of all relevant articles, as well as a justification for the use of the literature in place of clinical studies. You should establish comparability between the new device and the device used in the published literature in order to ensure that the data can be confidently extrapolated. We recommend that you consult OIVD to

Draft – Not for Implementation
Contains Nonbinding Recommendations

determine the suitability of literature, and techniques for its evaluation, to supplement or substitute for clinical performance studies.

IV. Labeling

For 510(k)s, the submission must include labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). For PMAs, your application must include copies of all proposed labeling for the device. (see 21 CFR 814.20(b)(10)). The following suggestions are aimed at assisting you in preparing proposed labeling that satisfies these requirements and final labeling that satisfies 21 CFR Parts 801 and 809.

Directions for Use

You should provide clear instructions that delineate the technological features of the specific device and how the device is to be used on patients. Instructions should encourage local/institutional training programs to familiarize users with the features of the device and how to use it in a safe and effective manner. Devices incorporating nucleic acid amplification should provide work-flow recommendations in the labeling.

Quality Control

We recommend that you provide a description of quality control measures that the laboratory should follow to help ensure proper device performance.

Interpretations and Precautions

We recommend that you provide the key for interpretations of results and specify the language to be used in reporting results. We recommend that you use standard nomenclature to describe alleles, genotypes, and mutations, and that you state the source of the nomenclature system. If you do not use standard nomenclature, you should provide a translation to standard nomenclature.

We recommend that you address the limitations of your device with statements in the labeling, for example:

- This test does not identify all alleles of CYP2D6.
- It is suspected that some mutations, alleles, or genotypes are private (found only in a small population or single family) and may not be detected by this test. Therefore you should interpret the results of the test with caution.
- This test should not be used for (name a reason or reasons).
- The presence of other (rare) mutations or polymorphisms may result in false positive or false negative results for this test.

Stability

Draft – Not for Implementation
Contains Nonbinding Recommendations

We recommend that you provide stability data to support the reagent shelf life that you state in your labeling. You should also provide recommendations for assessing the stability of input samples.

Performance

You should describe device performance in comparison to the reference method (bidirectional sequencing). Useful formats include 2 x 2 (or other N x N) tables, sensitivity and specificity, percent agreement, or other illustrative examples. You should calculate the sensitivity and specificity or percent agreement with their respective confidence intervals using all tested samples. Failed assays (e.g., inability to sequence the sample) should be considered disagreements for the purposes of reporting performance characteristics.

Appendix I: General considerations for planning and evaluating clinical studies

We recommend that you consult with the appropriate OIVD review divisions to determine the most appropriate strategies for your clinical studies. The following are some general recommendations that may be used when planning and evaluating clinical studies. An additional resource to consider when seeking guidance on reporting clinical and/or method comparison studies is the STARD (Standards for Reporting of Diagnostic Accuracy) statement (1), which was published in 2003 and is a roadmap for improving the quality of reporting of studies of diagnostic accuracy.³

1. Plan studies to support the intended use claim for the device with data that are representative of the population for whom the device is intended. Include a diversity of ethnic groups if the marker/mutation varies according to ethnicity.
2. Describe all protocols for internal and external evaluation studies. Clearly define the study population and inclusion and exclusion criteria and the chosen clinical endpoint. If literature is to be used to support your intended use, you should clearly explain the study population, inclusion/exclusion criteria, and endpoints in the publication and reflect how the device will be used in practice.
3. Establish uniform protocols for all external evaluation sites prior to study and follow them consistently throughout the course of data collection.
4. Use investigational sites and populations appropriate to the intended use and claims being sought. You should clearly outline efforts to define population sampling bias when this issue may impact performance.
5. Determine sample size prior to beginning the clinical study. The sample size should have sufficient statistical power to detect differences of clinical importance for each marker, mutation, or pattern. FDA will consider other approaches in cases with a small available sample size, for example, a disease allele having a low prevalence in the intended use population.
6. Describe the sampling method used in the selection and exclusion of patients. If it is necessary to use archived specimens or a retrospective design, provide pre-specified inclusion and exclusion criteria for samples, and adequate justification for why the sampled population is relevant to the patient population targeted for the intended use.

³Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49(1):7-18).

Draft – Not for Implementation
Contains Nonbinding Recommendations

7. For genetic tests, you should include samples from individuals with diseases or conditions that may cause false positive or false negative results with the device (i.e., within the differential diagnosis), if appropriate.
8. Analyze data for each individual test site and pooled over sites, if statistically and clinically justified. Justification of data pooling over sites should address variation between sites in prevalence, age, gender, and race/ethnicity.
9. Describe how the cut-off point (often the distinction between positive and negative, or the medical decision limit) will initially be set, and how it will be verified, if appropriate. If a cut-off is specified for each of multiple alleles, genotypes or mutations, describe the performance characteristics of each cutoff as it relates to its respective allele, genotype or mutation. The description of how each cut-off is determined should include the statistical method used [e.g., receiver operating characteristic (ROC) curve].
10. Diagnostic devices that assay the presence of a particular pattern (e.g., single nucleotide polymorphism (SNP) set, haplotype pattern), should ideally be validated in a prospective clinical trial. An example of such a device would be a test using a defined SNP set to discriminate between patients who may or may not experience an adverse event associated with a particular drug. Since it is statistically problematic to validate discrimination patterns in the same study in which they were defined, the simplest way to address this is to validate the pattern with an independent data set. Determination of the statistical significance of a retrospectively determined feature pattern may not be possible or minimally would call for careful use of complex statistical procedures, such as bootstrapping, or an explicit cross-validation scheme. Given that it can be easy to obtain a low misclassification rate for a retrospectively determined feature pattern even on random data, you should provide a valid procedure for obtaining the statistical significance of such a pattern. The simplest approach statistically is to evaluate the pattern on an independent data set from a prospective clinical trial, if that is feasible.
11. Account for all individuals and samples. Perform appropriate data audits and verification before submitting to FDA. Give specific reasons for excluding any patient or test result after enrollment.
12. Perform studies using appropriate methods for quality control. Describe the materials and methods used to assess quality control.